Thomas Levin, MD
Interventional Cardiology · Oak Lawn, ILNPI 1295773414
Payments from drug & device makers
Across 302 payments — averaging $91.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- M.a. Med Alliance S.A.$8K
- Bard Peripheral Vascular, Inc.$6K
- Penumbra, Inc.$3K
- Abiomed$1K
- Biotronik Inc.$898
- Cardiovascular Systems Inc.$820
- plus $8K from 31 others
What the payments were for
- Consulting fees$3252%
- Travel & lodging$2,63819%
- Food & beverage$10,28776%
- Education$3423%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| M.a. Med Alliance S.A. | 3 | $8,221 |
| Bard Peripheral Vascular, Inc. | 2 | $5,891 |
| Penumbra, Inc. | 13 | $2,922 |
| Abiomed | 16 | $1,218 |
| Biotronik Inc. | 30 | $898 |
| Cardiovascular Systems Inc. | 9 | $820 |
| Medtronic(2 entities) | 14 | $786 |
| Siemens Medical Solutions USA, Inc. | 9 | $676 |
| Boston Scientific | 7 | $599 |
| Johnson & Johnson | 27 | $545 |
| Inari Medical, Inc. | 1 | $500 |
| Tactile Systems Technology Inc | 46 | $488 |
| Novartis | 25 | $483 |
| Abbott | 8 | $465 |
| Edwards Lifesciences | 2 | $406 |
| Terumo Medical Corporation | 16 | $364 |
| Shockwave Medical, Inc | 7 | $273 |
| Amgen | 14 | $261 |
| Imperative Care, Inc | 3 | $204 |
| Endologix LLC | 2 | $197 |
| Esperion Therapeutics, Inc. | 5 | $194 |
| AstraZeneca | 7 | $183 |
| Atricure, Inc. | 1 | $178 |
| Novo Nordisk | 7 | $146 |
| Organogenesis Inc. | 1 | $146 |
| Cardiva Medical, Inc. | 4 | $136 |
| Boehringer Ingelheim | 3 | $90 |
| Heartflow, Inc. | 4 | $87 |
| Philips North America LLC | 1 | $78 |
| Pfizer | 4 | $61 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Teleflex LLC | 1 | $30 |
| Angiodynamics, Inc. | 1 | $22 |
| Merck | 1 | $16 |
| Chiesi USA, Inc. | 1 | $16 |
| Cordis US CORP. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$2,565
- Orsiro Mission$630
- Diamondback Coronary$603
- Impella$579
- FLOWTRIEVER CATHETER, S$500
- CT THROMBECTOMY SYSTEM KIT$500
- IN.PACT Admiral$325
- STINGRAY$230
- PRO-Kinetic Energy$225
- Passeo-18$225
- PK Papyrus$225
- ANGIOJET$182
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$178
- SAPIEN 3 Ultra RESILIA$163
- SYMPHONY CATHETER$160
- ENDOCROSS Device$147
- Torus Stent Graft System$147
- SYMPLICITY G3$147
- PURAPLY WOUND MATRIX$146
- AVVIGO Guidance System$132
How this compares
$27,704 in reported general payments places this provider in the 70th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 118 | $151,486 |
| XareltoRivaroxaban | 79 | $80,269 |
| EntrestoSacubitril/Valsartan | 54 | $59,918 |
| Repatha SureclickEvolocumab | 57 | $49,671 |
| JardianceEmpagliflozin | 47 | $45,610 |
| FarxigaDapagliflozin Propanediol | 14 | $21,500 |
| Praluent PenAlirocumab | 12 | $10,760 |
| BrilintaTicagrelor | 14 | $10,675 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $10,543 |
| Repatha SyringeEvolocumab | 18 | $6,268 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $6,162 |
| Atorvastatin Calcium | 476 | $5,778 |
| Metoprolol Succinate | 381 | $5,665 |
| Rosuvastatin Calcium | 233 | $3,807 |
| Ezetimibe | 183 | $3,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $61 | $151,486118 claims |
| Johnson & JohnsonXarelto | $545 | $80,26979 claims |
| NovartisEntresto | $483 | $59,91854 claims |
| Boehringer IngelheimJardiance | $90 | $45,61047 claims |
| AstraZenecaFarxiga, Brilinta | $183 | $32,17428 claims |
| Esperion Therapeutics, Inc.Nexlizet | $194 | $10,54312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Oak Lawn
- Jaafer GolzarOak Lawn$258K
- Charles DavidsonChicago$5.8M
- Ravi RamanaPalos Park$2.8M
- Mark RicciardiEvanston$2.2M
- Andrei PopElk Grove Village$1.9M
- Krishna Rocha SinghSpringfield$1.7M
- Bruce LewisMaywood$1.3M
- Justin LevisayEvanston$837K
- Atman ShahChicago$794K
- Laura DavidsonChicago$661K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.